FOLH1 and xerostomia: In a retrospective analysis by Feuerecker et al. [29], irreversible grade 1/2 xerostomia was observed in 26 (100%) patients after the first cycle of Ac-225-PSMA and led to early treatment termination for six (23%) patients.